Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Everest Medicines / Equity Capital Markets

Everest Medicines is a China-based biotech company with late-stage drug candidates in-licensed from partner pharmaceutical companies and biotechs.The company has experienced biotech investor managers as its top management. Its business model is to in-license drug candidates with unmet demand in China. We highlight the most interesting drug candidates is TROP-2 targeted Trodelvy which has a broad indication given the prevalent presence of this target in tumor cells. Its innovative antibiotic Xerava was in-vitro more potent than tigecycline but has not demonstrated efficacy in the clinical trial. It only shows non-inferiority to current therapies to cIAI. We think more studies, particularly head-to-head trials against tigecycline, are needed to demonstrate that it is superior to tigecycline. Both Etrasimod and Nefecon have a big indication and unmet demand in China.The company also has strong investor backing, from both global investors and healthcare specialist investors.

Everest Medicines is a China-based biotech company with late-stage drug candidates in-licensed from partner pharmaceutical companies and biotechs.The company has experienced biotech investor managers as its top management. Its business model is to in-license drug candidates with unmet demand in China. We highlight the most interesting drug candidates is TROP-2 targeted Trodelvy which has a broad indication given the prevalent presence of this target in tumor cells. Its innovative antibiotic Xerava was in-vitro more potent than tigecycline but has not demonstrated efficacy in the clinical trial. It only shows non-inferiority to current therapies to cIAI. We think more studies, particularly head-to-head trials against tigecycline, are needed to demonstrate that it is superior to tigecycline. Both Etrasimod and Nefecon have a big indication and unmet demand in China.The company also has strong investor backing, from both global investors and healthcare specialist investors.

Everest Medicines (云顶新耀) Pre-IPO: License-In Specialist Led by Biotech Investors

China

Everest Medicines Limited operates as a late clinical-stage biopharmaceutical company. The Company engages in licensing, clinical development, and commercialization of therapies for oncology, immunology, cardio-renal disease, and infectious disease. Everest Medicines markets its products in China and other emerging Asia Pacific markets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Everest Medicines (1952 HK)

Everest Medicines (云顶新耀) Pre-IPO: License-In Specialist Led by Biotech Investors

Everest Medicines is a China-based biotech company with late-stage drug candidates in-licensed from partner pharmaceutical companies and...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)